Indefinite Delivery Contract SPE2DU25D9770

The federal contract IDV award SPE2DU25D9770 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military health facilities worldwide.

The IDC was awarded under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which aims to establish multiple Prime Vendor Contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, the U.S. Coast Guard, Designated Providers, and Other Government Agencies. The unrestricted solicitation, expected to be issued in March 2024, has an estimated total value of $30.3 billion and will cover medical pharmaceuticals in the 6505 stock catalog/schedule and the current National Drug Code (NDC) database. Awards will be made on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items.